iPROACTIVE

iPROACTIVE (interprofessional Partnership in Reduction of Opioid-related Adverse Consequences Through InnoVative Efforts) is a clinical study evaluating a novel hospital-based opioid reduction program aimed at minimizing opioid use.

The main objective of the study is to reduce the number of treatment days with newly prescribed or increased opioid doses. The primary intervention of this confirmatory, single-center, prospective, open-label, randomized, and controlled trial consists of individualized recommendations for opioid reduction (“deprescribing”), issued by an interprofessional team of physicians and pharmacists.

The study will include adult patients who are hospitalized at the Cantonal Hospital Baden, have received opioids for at least three consecutive days, and for whom dose reduction or discontinuation is planned.

The intervention group will receive an individualized opioid reduction plan and patient education, while the control group will continue to receive standard care. Part of the patient education is the provision of a patient brochure. This brochure was co-created, designed, and implemented collaboratively. During the creation phase and after prototyping, feedback was gathered from a focus group consisting of various hospital stakeholders as well as patients.

Applicant and Project Lead:
Prof. Dr. Anna Lisa Martin-Niedecken, Institute for Design Research, ZHdK
Dr. phil. Dominik Stämpfli, Clinical Pharmacist & Research Scientist, ETH Zurich

Collaboration:
Digital Health Design Living Lab, Zurich University of the Arts (ZHdK)
Cantonal Hospital Baden

Design Direction:
Patrik Ferrarelli, M.A.

Project Duration:
February 2025 – July 2025

Funding:
Pharmacoepidemiology Research Group,
Institute of Pharmaceutical Sciences, ETH Zurich

iPROACTIVE
iPROACTIVE